Timeline of Translational Formulation Technologies for Cancer Therapy: Successes, Failures, and Lessons Learned...

Area of Science:

• Oncology
• Pharmaceutical Sciences
• Drug Delivery

Background:

• Cancer therapy formulation development has evolved significantly, aiming for improved drug bioavailability, efficacy, and safety.
• Numerous formulations have reached the market, while others have failed, offering valuable lessons for the scientific community.

Purpose of the Study:

• To review the successes and failures of approved formulations for peptide-based therapy, chemotherapy, and radiotherapy.
• To summarize products in Phase III clinical trials over the last five years.
• To outline future research trends in clinically translatable cancer treatment formulations.

Main Methods:

• Review of approved formulations in Europe and by the FDA for major cancer therapy types.
• Analysis of formulation development from early prolonged-release systems to recent biodegradable microspheres.
• Summary of Phase III clinical trial data from the past five years.

Main Results:

• Approved formulations demonstrate advancements in drug delivery for various cancer therapies.
• Both successes and failures provide critical insights into formulation design and clinical translation.
• Ongoing Phase III trials indicate a focus on innovative drug delivery systems.

Conclusions:

• The evolution of cancer therapy formulations has yielded significant improvements but also highlighted challenges.
• Understanding past successes and failures is crucial for guiding future research and development.
• Future efforts should focus on creating clinically translatable formulations to enhance cancer treatment outcomes.